Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV/EBV specific CTLs post-HSCT
NCT02456610Phase 1Unknown
- Sponsor
- Academy of Military Medical Sciences
- Start
- May 2015
- Primary completion
- Jul 2016
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of cytomegalovirus/Epstein-Barr virus-specific cytotoxic T lymphocytes in cytomegalovirus infection (CMV) and Epstein-Barr virus infection, sponsored by Academy of Military Medical Sciences. Primary endpoints: Toxicity of adoptive transfer of CMV/EBV specific CTLs at 24 hours and Assessment of viral load response to the CTL infusion at 3 months. Status: unknown.
02
Drugs
cytomegalovirus/Epstein-Barr virus-specific cytotoxic T lymphocytes
03
Conditions
cytomegalovirus infection (CMV)Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT02456610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02456610.